Immunotherapy of cancer through targeting of the p53 tumor antigen

• Authors: S. Zwaveling , der_ Burg S.H. Van_ , A.G. Menon , C.J.M. Melief , R. Offringa
• Languages of publication: EN

Abstracts

EN

The expression of the p53 tumor suppressor protein is frequently increased in a great variety of human cancers, making this antigen an attractive candidate for targeting therapeutic T cell immunity. However, potential complications as a result of immunological tolerance or auto-immune pathology must be taken into account when exploiting this ubiquitously expressed auto-antigen for immunotherapy of cancer.

Keywords

EN

CANCER IMMUNOTHERAPY; P53 TUMOR

Discipline

• IMMUNOLOGY: IMMUNOLOGY

• Publisher: Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
• Journal: Archivum Immunologiae et Therapiae Experimentalis
• Year: 2002
• Volume: 50
• Issue: 5
• Pages: 297-306

Contributors

author

S. Zwaveling

author

der_ Burg S.H. Van_

author

A.G. Menon

author

C.J.M. Melief

author

R. Offringa

• Document Type: REVIEW
• Publication order reference: S. Zwaveling, Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Tumor Immunology Group, Albinusdreef 2, 2333 ZA Leiden, The Netherlands